Oncopeptides reinitiates patient enrollment to the melflufen clinical program following a temporary pause due to the COVID-19 pandemic

STOCKHOLM — May 28, 2020 — Oncopeptides AB (Nasdaq Stockholm: ONCO) announces that the company starts patient enrollment to its clinical program following the temporary recruitment pause due to the COVID-19 pandemic, announced on March 20. The program will be reinitiated at sites where local regulations and patient safety enable a restart and where recruitment, treatment and adherence to protocol, as well as safety and data monitoring are feasible.The temporary pause did not impact the pivotal phase 2 HORIZON study and the company is on track to submit a file to the FDA based on these data